Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients

医学 内科学 乳腺癌 曲妥珠单抗 肿瘤科 卡铂 多西紫杉醇 胃肠病学 化疗 癌症 顺铂
作者
Yibo Chen,Tianyi Zhang,Rui Zhang,X B Cao
出处
期刊:Cancer Biotherapy and Radiopharmaceuticals [Mary Ann Liebert, Inc.]
卷期号:39 (6): 435-440
标识
DOI:10.1089/cbr.2023.0175
摘要

Objective: Pyrotinib, a new irreversible dual pan-human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase inhibitor blocking EGFR and HER2, has achieved a promising efficacy for advanced HER2-positive (HER2+) breast cancer. This study intended to further investigate the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2+ breast cancer treatment. Methods: Thirty-eight HER2+ breast cancer patients who received neoadjuvant pyrotinib and trastuzumab plus chemotherapy (docetaxel and carboplatin) were retrospectively reviewed. Clinical response by Response Evaluation Criteria in Solid Tumors (RECIST), pathological complete response (pCR), and adverse events data was retrieved. Results: According to the RECIST, the complete response rate was 0.0%, 10.5%, and 15.8% after second-cycle, fourth-cycle, and sixth-cycle therapy, respectively; whereas the objective response rate was 76.3%, 92.1%, and 100.0%, accordingly. The total pCR (tpCR) rate was 52.6%, the pCR rate of the breast was also 52.6%, and the pCR rate of lymph nodes was 86.8%. The tpCR rate was lower in patients with HER2 immunohistochemistry (IHC)++ and amplification by fluorescent in situ hybridization (FISH) than in those with HER2 IHC+++ (14.3% vs. 61.3%, p = 0.024), which was also lower in patients with Ki-67 expression ≥30% than in those with Ki-67 expression <30% (40.0% vs. 76.9%, p = 0.031). The common adverse events included diarrhea (84.2%), anemia (73.7%), nausea and vomiting (63.2%), fatigue (50.0%), hypomagnesemia (44.7%), leukopenia (42.1%), thrombocytopenia (39.5%), elevated transaminase (36.8%), and pruritus (31.6%). Conclusions: Pyrotinib and trastuzumab plus chemotherapy serve as an acceptable neoadjuvant regimen exhibiting good efficacy and tolerance in HER2+ breast cancer patients, while further large-scale validation is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
姜惠完成签到 ,获得积分10
1秒前
小脸红扑扑完成签到 ,获得积分10
2秒前
奋斗的凡完成签到 ,获得积分10
2秒前
3秒前
zhutier完成签到,获得积分10
4秒前
wrr完成签到,获得积分10
4秒前
WxChen完成签到,获得积分10
4秒前
开朗艳一完成签到,获得积分10
6秒前
Wonder完成签到,获得积分10
7秒前
yang完成签到,获得积分10
9秒前
123123完成签到 ,获得积分10
10秒前
温暖宛筠完成签到,获得积分10
10秒前
小欣6116完成签到,获得积分10
11秒前
请叫我风吹麦浪应助冬月采纳,获得10
11秒前
LIUYONG发布了新的文献求助10
12秒前
12秒前
肖雪依完成签到,获得积分10
12秒前
影子完成签到,获得积分10
13秒前
14秒前
晨珂完成签到,获得积分10
14秒前
Florencia发布了新的文献求助10
16秒前
xiezhuochun发布了新的文献求助10
17秒前
17秒前
同瓜不同命完成签到,获得积分10
19秒前
牛马哥发布了新的文献求助10
20秒前
温婉的松鼠完成签到,获得积分10
20秒前
21秒前
辛勤的寄瑶完成签到,获得积分10
21秒前
Lauren完成签到 ,获得积分10
22秒前
23秒前
忆枫完成签到,获得积分10
27秒前
炒鸡小将发布了新的文献求助10
27秒前
花壳在逃野猪完成签到 ,获得积分10
27秒前
27秒前
银子吃好的完成签到,获得积分10
28秒前
西瓜霜完成签到 ,获得积分10
28秒前
科研废物完成签到 ,获得积分10
30秒前
冬月完成签到,获得积分10
30秒前
30秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029